- Home
- MESO vs SDHC Comparison
MESO vs SDHC Comparison
Compare MESO & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- SDHC
- Stock Information
- Founded
- MESO 2004
- SDHC 2008
- Country
- MESO Australia
- SDHC United States
- Employees
- MESO N/A
- SDHC N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- SDHC
- Sector
- MESO Health Care
- SDHC
- Exchange
- MESO Nasdaq
- SDHC Nasdaq
- Market Cap
- MESO 1.2B
- SDHC 1.5B
- IPO Year
- MESO N/A
- SDHC 2024
- Fundamental
- Price
- MESO $14.63
- SDHC $27.95
- Analyst Decision
- MESO Strong Buy
- SDHC Hold
- Analyst Count
- MESO 4
- SDHC 6
- Target Price
- MESO $13.50
- SDHC $32.80
- AVG Volume (30 Days)
- MESO 552.8K
- SDHC 83.8K
- Earning Date
- MESO 08-28-2024
- SDHC 12-31-2024
- Dividend Yield
- MESO N/A
- SDHC N/A
- EPS Growth
- MESO N/A
- SDHC N/A
- EPS
- MESO N/A
- SDHC 4.71
- Revenue
- MESO $5,902,000.00
- SDHC $905,304,000.00
- Revenue This Year
- MESO $66.05
- SDHC $27.04
- Revenue Next Year
- MESO $348.27
- SDHC $14.68
- P/E Ratio
- MESO N/A
- SDHC $5.91
- Revenue Growth
- MESO N/A
- SDHC 17.46
- 52 Week Low
- MESO $1.61
- SDHC $20.55
- 52 Week High
- MESO $19.15
- SDHC $39.50
- Technical
- Relative Strength Index (RSI)
- MESO 64.37
- SDHC 29.17
- Support Level
- MESO $12.20
- SDHC $31.04
- Resistance Level
- MESO $19.15
- SDHC $33.02
- Average True Range (ATR)
- MESO 0.98
- SDHC 1.21
- MACD
- MESO 0.37
- SDHC -0.44
- Stochastic Oscillator
- MESO 48.93
- SDHC 7.81
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.